# Day 6 — Final Reviewer-Agent Gate Review

**Project:** PYRIN-PLAQUE Digital Twin · **Gate:** Day-6 final cross-artifact audit before Day-7 packaging.
**Reviewer:** adversarial reviewer agent (`host.llm`, reasoning model). Severity: BLOCKER / MAJOR / MINOR / INFO.

| # | Check | Status | Severity | Finding |
|---|-------|--------|----------|---------|
| 1 | Are all claims grounded in source or computed artifact? | **PASS** | INFO | Consistency audit shows 8/8 checks resolved with no unattributed confidence language |
| 2 | Are all numbers traceable to tables/code? | **PASS** | INFO | MEFV %, deltas, effect sizes, ODE sensitivity, and priority scores each cite specific saved tables |
| 3 | Are all figures traceable to scripts and figure cards? | **PASS** | INFO | 5 figures in day6_final_figure_inventory.csv each carry script, env, checksum, and figure card |
| 4 | Are GSDME and GSE120521 pairing language consistent? | **PASS** | INFO | GSDME fixed to GENERIC_PYROPTOSIS (14/14) and GSE120521 pairing uses one canonical assumption-hedged statement across all 3 files |
| 5 | Is no 'first ever' language present? | **PASS** | INFO | No first-claim phrasing found; novelty framed conservatively against 6 prior athero papers |
| 6 | Are pyrin and NLRP3 separated correctly? | **PASS** | INFO | Backbones exclude 5 shared downstream nodes; NLRP3 consistently labeled saturated comparator |
| 7 | Are shared downstream nodes handled correctly? | **PASS** | INFO | PYCARD/CASP1/GSDMD/IL1B/IL18 assigned zero pyrin-specificity credit; GSDME treated as generic |
| 8 | Are Day3/4/5 caveats carried into the integrated results? | **PASS** | INFO | Integrated report sections 5-10 explicitly restate sparse MEFV, AC/PA mixed, myeloid confounding, n=4 FPKM, and ODE threshold caveats |
| 9 | Is the ODE described as dimensionless and non-clinical? | **PASS** | INFO | ODE labeled dimensionless, uncalibrated, hypothesis-generating, non-clinical throughout report and cards |
| 10 | Is druggability plausibility-only? | **PASS** | INFO | Druggability note explicitly separates tractability from pyrin-selective efficacy claims, no drug/efficacy assertion |
| 11 | Does the demo script avoid overclaiming? | **PASS** | INFO | Script/storyboard explicitly frame work as unvalidated hypothesis engine with preserved null/confounded results |
| 12 | Are all reviewer-agent gates linked? | **PASS** | INFO | Section 11 plus usage statement link all 6 gates (Day1-Day6) with pass/flag counts |
| 13 | Should Day 7 proceed? | **PASS** | INFO | All 12 preceding audit checks pass with no unresolved blockers or majors; packaging can proceed |

## Verdict: **PROCEED**  (PASS 13 · FLAG 0 · FAIL 0; BLOCKER 0 · MAJOR 0 · MINOR 0)

### Key findings
- Cross-artifact consistency audit resolved 8/8 checks with no unsafe confidence language
- GSDME reclassified generic pyroptosis and GSE120521 pairing statement made canonical across all files
- Pyrin vs NLRP3 backbone separation and zero-credit treatment of shared downstream nodes correctly enforced
- Day3-5 caveats (sparse MEFV, AC/PA mixing, myeloid confounding, low-n FPKM, ODE threshold) all propagated into integrated report
- ODE and druggability sections correctly scoped as non-clinical/plausibility-only, and demo materials avoid overclaiming
- All 6 reviewer-agent gates linked with pass/flag counts; no blockers or majors identified, Day 7 packaging cleared to proceed

**No blockers, majors, or minors. Day 7 packaging may proceed.**